Introduction 47
Meningoencephalitis of unknown aetiology (MUA) describes all clinically 48 diagnosed cases of granulomatous meningoencephalitis (GME), necrotising 49 meningoencephalitis (NME) and necrotising leucoencephalitis (NLE) that lack 50 histopathological confirmation (Coates and Jeffery, 2014) . A clinical diagnosis can be 51 achieved based on a combination of neurological examination results, magnetic 52 resonance imaging (MRI) findings and cerebrospinal fluid (CSF) abnormalities 53 (Coates and Jeffery, 2014) . The exact aetiology and pathophysiology of MUA are 54 currently unknown, but the cornerstone of medical treatment is immunosuppressive 55 therapy. Several treatment protocols using different immunomodulating drugs, 56 resulting in different long-term survival times have been reported (Munana and 57 Luttgen, 1998; Jung et al., 2007; Coates et al., 2007; Granger et al., 2010; Flegel et 58 al., 2011; Beckmann et al., 2015; Barnoon et al., 2016) . 59
60
Although several studies have focused on long-term survival, little is known 61 about early survival and initial response to therapy of dogs diagnosed with MUA. The 62 primary aim of this study was therefore to evaluate early survival and initial response 63 to immunosuppressive therapy in those dogs. A secondary aim was to investigate 64 possible prognostic factors for 7-day survival after diagnosis of MUA. It was 65
hypothesised that a substantial portion of dogs with MUA would succumb in the first 66 week after diagnosis despite appropriate treatment and monitoring. It was further 67
hypothesised that specific characteristics of the clinical presentation, neurological 68 examination, clinical pathology abnormalities, imaging findings and type of treatment 69 would be associated with 7-day survival in dogs with a presumptive diagnosis of 70
MUA. 71 72

Materials and methods 73
Case selection 74
The electronic medical database of the Small Animal Referral Hospital, Royal 75
Veterinary College, University of London, was searched between January 2006 and 76 April 2015 for dogs diagnosed with MUA. Dogs were included based on the criteria 77 used by Granger et al. (2010) , if they had: (1) complete medical records available; (2) 78 a complete neurological examination performed leading to a focal or multifocal 79 intracranial neuroanatomical localization; (3) inflammatory CSF analysis; (4) MR 80 imaging of the brain demonstrating single, multiple or diffuse intra-axial hyperintense 81 lesions on T2W images; and (5) if 7-day follow-up information was available. Dogs 82 with histopathological confirmation of MUA only needed to fulfill inclusion criteria 83
(1) and (5). In this study, the term MUA was used for all dogs included in the study, 84 including those with histopathological confirmation of GME, NME or NLE. at least 7 days after diagnosis of MUA, while an unsuccessful outcome was defined as 140 death in the first 7 days after diagnosis. For dogs that died in the first week after 141 diagnosis, information on whether dogs were euthanased at the owner's request after 142 diagnosis without treatment, they failed to recover from general anesthesia after MRI, 143 or they died or were euthanased due to progression of disease after recovery from 144 general anesthesia was recorded. Dogs that did not survive general anaesthesia or 145 were euthanased at the owner's request after diagnosis without treatment were not 146 included for further analysis. 147
148
Statistical analysis 149
Outcome was defined as dead or alive 7 days after diagnosis. Data analysis 150 was performed using a statistical software package (Prism, Graphpad Software). A 151
Mann-Whitney U test was used to compare age, weight, duration of clinical signs 152 prior to diagnosis, venous blood glucose and lactate levels, white blood cell (total, 153 neutrophil and lymphocyte) count on CBC, TNCC/TP/neutrophil percentage in CSF, 154 between dogs that were dead or alive 1 week after diagnosis. A Fisher's exact test was 155 used to compare differences in sex, treatment prior to diagnosis, presence of seizures 156 and cluster seizures, mentation (BAR, QAR, obtundation, stupor, coma),neuroanatomical localisation (multifocal, forebrain, brainstem, central vestibular), 158 treatment after diagnosis (steroids, cytosine arabinoside, mannitol) and imaging 159 findings (lesion localisation, meningeal or parenchymal contrast enhancement, mass 160 effect, brain herniation, flattening gyri/sulci, rostral or caudal transtentorial herniation, 161 foramen magnum herniation) between dogs that were dead or alive 1 week after 162
diagnosis. 163 164
A binary response mixed model was carried out using SPSS (Statistical 165
Package for the Social Sciences v. 21.0.1, SPSS). The binary response variable was 166 whether the dog was dead or alive 7 days after diagnosis. Factors found to be 167 significant at the univariate level were taken forward for multivariate analysis. 168
Bodyweight, duration of clinical signs, lactate concentration on venous blood gas 169 analysis, TNCC on CSF analysis and percentage of neutrophils in CSF were modeled 170 as continuous fixed effects. Mentation was modeled as a categorical fixed effect, and 171 the presence of seizures, cluster seizures and cytosine arabinoside administration were 172 modeled as binomial fixed effects. Breed was included as a random effect, with cross 173 breeds coded plainly as 'cross breed' due to unknown parentage. This random effect 174 took into account the genetic non-independence of multiple members of the same 175 breed in the study population, and possible demographic and environmental factors. 176
All models were checked for multicollinearity, identified from inflated standard errors 177 in the models, and thus avoided. Model fit was assessed using the deviance and 178 
Diagnostic findings 209
Results of CBC and biochemistry profile were available in 97 dogs (84%). 210
Leucocytosis was present in 13 dogs (13%) and lymphopenia in 32 dogs (33%). 211
Serology and/or PCR analysis for Toxoplasma gondii, Neospora caninum and canine 212 distemper virus were available and negative in 82 dogs (71%). Lactate and glucose 213 concentrations on venous blood gas analysis were available in 49 dogs (42%), 214 revealing an increased lactate and/or glucose concentration in nine (18%) and 12 215 (24%) dogs, respectively. CSF analysis was not performed in 20 dogs (17%); it 216 revealed no abnormalities in three dogs (3%); and a pleocytosis in the remaining 93 217 dogs (80%). In the three dogs with normal TNCCs, complete necropsy revealed GME 218 (n=1), NME (n=1) or NLE (n=1). For the dogs with a pleocytosis (n=93), median 219 TNCC was 80 WBC/mm 3 (6-2560 WBC/mm 3 ). For the dogs that died in the first 220 week after diagnosis, median percentage of lymphocytes, neutrophils and 221 monocytes/macrophages was 54%, 5% and 24%, respectively, compared to dogs that 222 survived the first week after diagnosis, where percentages were 66%, 1% and 23%, 223 significantly associated with outcome in this model (Table 1) . 273
274
A binary response mixed model was performed on factors found to be 275 significant at the univariate level. Three variables were significantly associated with 276 poor outcome in the final model: percentage of neutrophils in CSF, decreased 277 mentation at presentation, and a history of seizures (Table 2) . Dogs with a higher 278 percentage of neutrophils were at an increased risk of death at 1 week (mean ± 279 standard error dead, 14.88 ± 4.01; alive, 6.31 ± 1.40). Dogs with decreased mentation 280 at presentation were at increased risk of death within 1 week (% dead at 1 week BAR, 281 20% vs. stupor, 66.7%). Dogs presented as BAR had an 18.33 increased odds of 282 being alive at 1 week compared to those presented in a stuporous state. Finally, dogs 283 with a history of seizures were at an increased risk of death at 1 week (dead at 1 week 284 no seizures, 19.5% vs. seizures, 51.7%). Dogs without seizures had 4.20 increased 285 odds of being alive at 1 week compared to those with seizures. ROC-analysis revealed 286 that none of the significant continuous variables was able to reliably differentiate 287 between good and poor short-term outcome in dogs with MUA (Fig. 1) . In a recent study by Sharma and Holowaychuk (2015) , increased venous 305 lactate concentrations were a risk factor for non-survival to hospital discharge in dogs 306 with head trauma. Additionally, hyperglycaemia has been associated with severity of 307 injury in cases of head trauma in dogs and cats, but not with outcome (Syring et al., 308 2001) . In the present study, blood glucose and lactate levels were measured on 309 admission or before MR imaging on standard venous blood gas analysis. No 310 significant difference was found in blood glucose levels between dogs that did or did 311 not survive the first week after diagnosis. In the univariate analysis, lactate 312 concentrations were significantly increased in dogs with a poor outcome, but this 313 result was not confirmed in the multivariate analysis. As both measurements were 314 only available for review in approximately 20% of cases, further prospective studies 315 are required before accurate conclusions can be drawn. 316
317
This study identified some potential risk factors for death in the first 7 days 318 after diagnosis of MUA, including seizures and/or decreased mentation at 319 presentation, as has been reported previously (Bateman and Parent, 1999; Coates et 320 al., 2007) . Although it is possible that these dogs represent a group of animals with a 321 more severe clinical phenotype, we cannot exclude the possibility that the necessity of 322 administering anti-epileptic drugs in these dogs was associated with increased 323 sedation and therefore contributed to a further decline of their neurological function. 324
In contrast to results of a recent study (Lowrie et al., 2013) , higher neutrophil 325 percentage on CSF analysis was significantly associated with increased risk of death 326 in the first week after a diagnosis of MUA. However, our ROC-curve did not generate 327 a reliable threshold value with combined high sensitivity and specificity to predict 328 survival, so the exact neutrophil percentage should not be considered a useful tool for 329 assessing prognosis in individual animals with MUA. 
